To address the issue that existing documents do not consistently provide patients with clear, easily understood information about their prescription medications, FDA proposed in May 2023 to amend its human prescription drug product labeling regulations for Medication Guides that, if finalized, will require a new type of information known as Patient Medication Information (PMI).